Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis

Follow-up of Study C87040: Multicentre, Double-blind Study to Describe the Efficacy and Safety of Re-treatment With CDP870 (Certolizumab Pegol) Subcutaneous at 2 Different Dose Regimens (400 mg Initial Dose at Week 0 With 200 mg Every 2 Weeks Thereafter and 400 mg Every 2 Weeks) or Placebo for 12 Weeks, in Subjects Suffering From Moderate-to-severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy and/or Phototherapy and/or Photochemotherapy, Having Responded to Treatment in Study C87040 and Having Subsequently Relapsed

The primary objective is to assess differences in PASI scores between Week 12 of Study C87040 [NCT00245765] and Week 12 of re-treatment in this study.

Inclusion Criteria:

• Subject having responded to treatment at Week 12 in study C87040 and having relapsed during the follow-up period
• Female subjects either postmenopausal for at least one year, surgically incapable of childbearing, or effectively practising an acceptable method of contraception.Subjects agreed to continue using adequate contraception during the study and for 12 weeks after the last dose of CDP870

Exclusion Criteria:

• Subjects with erythrodermic, guttate, generalized pustular form of psoriasis
• Any recent serious or life-threatening infection or any current sign or symptom that may indicate an infection (e.g., fever, cough)
• Positive hepatitis B surface antigen test and /or hepatitis C antibody test results
• Positive human immunodeficiency virus (HIV) test result
• White blood cell counts less than 4000 per cubic millimeter or more than 20000 per cubic millimeter
• Suspected or diagnosed demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis)
• Systemic Lupus Erythematosus
• Participation in a clinical study within the past 3 months except Study C87040
• Any other condition, which in the Investigator's judgment would make the subject unsuitable for inclusion in the study